Sponsors

Blood test to reduce late detection of lung cancer

Oncimmune, a global immunodiagnostics group, has welcomed the presentation of data by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.

In a randomised, controlled trial of 12,209 people in Scotland at high risk of developing lung cancer, it was shown that more people were diagnosed at an early stage of the disease in the two years after taking the EarlyCDT Lung test than those in the control arm who received standard clinical care.

The findings, presented at the 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC) in Barcelona, are an important validation of Oncimmune’s diagnostic platform technology which harnesses the power of the immune system, to detect evidence of the body’s natural response to cancer. The technology can detect cancer four years or more before standard clinical diagnosis.

www.oncimmune.com

Latest Issues

DIA-MHRA Global Summit

Senate House, Malet Street, London, WC1E 7HU
16-17 November, 2026

UK NEQAS for Microbiology & Parasitology Annual Scientific Meeting 2026

The Royal National Hotel, 38 – 51 Bedford Way, London, WC1H 0DG
27 November, 2026

UK NEQAS webinar: Epigenetics

Online
1 December, 2026

Weqas Annual POCT Conference 2026

London, Venue - TBC
8-9 December, 2026

UK NEQAS webinar: Fresh Muscle Biopsies

Online
8 December, 2026